Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines

Dermatologic Surgery

Volumn 36, Issue SUPPL. 4, 2010, Pages 2146-2154

  Sattler, Gerhard ^a   Callander, Michael J ^b   Grablowitz, Doris ^c   Walker, Torsten ^d   Bee, Eva K ^e   Rzany, Berthold ^f   Flynn, Timothy Corcoran ^g   Carruthers, Alastair ^h  

^a Rosenparkklinik   (Germany)

^b Face and Body Clinic   (United Kingdom)

^c Medizinisch Îsthetisches Zentrum   (Austria)

^d Privatpraxis für Hautkrankheiten   (Germany)

^e Hautartzpraxis Stengel and Bee ^*  (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ESTHETICS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHOTOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WRINKLE;

ADULT; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; FOREHEAD; HUMANS; MIDDLE AGED; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; SKIN AGING; YOUNG ADULT;

EID: 78650092929     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2010.01706.x     Document Type: Article

References (13)

1. Inoue K, Fujinaga Y, Watanabe T, et al,. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 1996; 64: 1589-94.
2. Jost WH, Kohl A, Brinkmann S, Comes G., Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J Neural Transm 2005; 112: 905-13.
3. Carruthers A, Carruthers J., Botulinum toxin products overview. Skin Ther Lett 2008; 13: 1-4.
4. Roggenkämper P, Jost WH, Bihari K, et al,. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006; 113: 303-12.
5. Benecke R, Jost WH, Kanovsky P, et al,. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005; 64: 1949-51.
6. Carruthers JA, Lowe NJ, Menter MA, et al,. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002; 46: 840-9.
7. Ascher B, Zakine B, Kestemont P, et al,. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004; 51: 223-33.
8. De Maio M, Rzany B., Botulinum toxin in aesthetic medicine. Heidelberg: Springer; 2007. ISBN-10: 3540340947, ISBN-13: 978-3540340942.
9. Carruthers A, Carruthers J., Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg 2005; 31: 1297-303.
10. Carruthers A, Carruthers J, Said S., Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 2005; 31: 414-22.
11. Lowe P, Patnaik R, Lowe N., Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. J Am Acad Dermatol 2006; 55: 975-80.
12. Monheit G, Carruthers A, Brandt F, Rand R., A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 2007; 33: S51-9. (Pubitemid 46051400)
13. Ascher B, Rzany B, Grover R., Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Derm Surg 2009; 35: 1478-86.